MX361499B - Baricitinib deuterado. - Google Patents

Baricitinib deuterado.

Info

Publication number
MX361499B
MX361499B MX2015002040A MX2015002040A MX361499B MX 361499 B MX361499 B MX 361499B MX 2015002040 A MX2015002040 A MX 2015002040A MX 2015002040 A MX2015002040 A MX 2015002040A MX 361499 B MX361499 B MX 361499B
Authority
MX
Mexico
Prior art keywords
baricitinib
deuterated
formula
compound
pharmaceutically acceptable
Prior art date
Application number
MX2015002040A
Other languages
English (en)
Other versions
MX2015002040A (es
Inventor
Roger D Tung
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Publication of MX2015002040A publication Critical patent/MX2015002040A/es
Publication of MX361499B publication Critical patent/MX361499B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención, en una modalidad, proporciona un compuesto de la Fórmula I: (ver Fórmula) o una sal farmacéuticamente aceptable del mismo, en donde las variables mostradas en la Fórmula I son como se define en la especificación.
MX2015002040A 2012-08-17 2013-08-15 Baricitinib deuterado. MX361499B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261684196P 2012-08-17 2012-08-17
US201361780661P 2013-03-13 2013-03-13
PCT/US2013/055170 WO2014028756A1 (en) 2012-08-17 2013-08-15 Deuterated baricitinib

Publications (2)

Publication Number Publication Date
MX2015002040A MX2015002040A (es) 2015-06-05
MX361499B true MX361499B (es) 2018-12-06

Family

ID=49034261

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015002040A MX361499B (es) 2012-08-17 2013-08-15 Baricitinib deuterado.

Country Status (10)

Country Link
US (3) US9540367B2 (es)
EP (2) EP3492472A1 (es)
AU (1) AU2013302519B2 (es)
BR (1) BR112015003153A2 (es)
CA (1) CA2880083A1 (es)
EA (1) EA031716B1 (es)
ES (1) ES2717279T3 (es)
IN (1) IN2015DN01102A (es)
MX (1) MX361499B (es)
WO (1) WO2014028756A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015003153A2 (pt) 2012-08-17 2017-07-04 Concert Pharmaceuticals Inc baricitinib deuterado
WO2015166434A1 (en) * 2014-05-01 2015-11-05 Sun Pharmaceutical Industries Limited Crystalline form of baricitinib
EP3179991B1 (en) 2014-08-11 2021-10-06 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a bcl-2 inhibitor
SI3179992T1 (sl) 2014-08-11 2022-09-30 Acerta Pharma B.V. Terapevtske kombinacije zaviralca BTK, zaviralca PD-1 in/ali zaviralca PD-L1
AR101504A1 (es) 2014-08-11 2016-12-21 Acerta Pharma Bv Combinaciones terapéuticas de un inhibidor de la btk, un inhibidor de la pi3k, un inhibidor de la jak-2, y/o un inhibidor de la cdk4/6
WO2016125080A2 (en) * 2015-02-02 2016-08-11 Sun Pharmaceutical Industries Limited Process for the preparation of baricitinib and an intermediate thereof
RU2603959C1 (ru) * 2015-11-13 2016-12-10 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") ДИХЛОРАЦЕТАТ {3-[4-(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-ПИРАЗОЛ-1-ИЛ]-1-ЭТИЛСУЛЬФОНИЛ-АЗЕТИДИН-3-ИЛ}-АЦЕТОНИТРИЛА В КАЧЕСТВЕ ИНГИБИТОРА ЯНУС КИНАЗ
RU2601410C1 (ru) * 2015-11-13 2016-11-10 ЗАО "Р-Фарм" {3-[(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АЗОЛИЛ]АЗЕТИДИН-3-ИЛ}АЦЕТОНИТРИЛЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС КИНАЗ
CN107334738B (zh) * 2016-04-28 2021-02-09 天津科伦药物研究有限公司 一种含巴瑞克替尼的药物组合物及其制备方法和用途
US20200353419A1 (en) 2017-11-22 2020-11-12 Dauntless 1, Inc. Membrane emulsification device for microsphere creation
EP3713545A1 (en) 2017-11-22 2020-09-30 Dauntless 1, Inc. Therapeutic compound formulations
US10766900B2 (en) 2017-12-29 2020-09-08 Formosa Laboratories, Inc. Baricitinib intermediate, method for forming Baricitinib intermediate, and method for preparing Baricitinib or pharmaceutically acceptable salt thereof
PT3773593T (pt) 2018-03-30 2024-06-25 Incyte Corp Tratamento da hidradenite supurativa com inibidores de jak
EP3775284A1 (en) 2018-03-30 2021-02-17 Incyte Corporation Biomarkers for inflammatory skin disease
SG11202010092XA (en) 2018-04-13 2020-11-27 Incyte Corp Biomarkers for graft-versus-host disease
IL285999B2 (en) 2019-03-05 2026-01-01 Incyte Corp JAK1 inhibitor pathway for the treatment of chronic lung allograft dysfunction
US11624751B2 (en) 2019-03-19 2023-04-11 Incyte Corporation Biomarkers for vitiligo
WO2020236950A1 (en) 2019-05-21 2020-11-26 Dauntless 1, Inc. Therapeutic microsphere formulations containing charged polymers
US20220372135A1 (en) 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
US12360120B2 (en) 2019-10-10 2025-07-15 Incyte Corporation Biomarkers for graft-versus-host disease
JP2022551649A (ja) 2019-10-10 2022-12-12 インサイト・コーポレイション 移植片対宿主病のバイオマーカー
JP7518900B2 (ja) 2019-10-16 2024-07-18 インサイト・コーポレイション 皮膚エリテマトーデス及び扁平苔癬（ｌｐ）の治療のためのｊａｋ１阻害剤の使用
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
CA3177830A1 (en) 2020-05-13 2021-11-18 Maria BECONI Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
TW202237125A (zh) 2020-12-04 2022-10-01 美商英塞特公司 用於治療皮膚疾病之jak抑制劑與維生素d類似物
MX2023008141A (es) 2021-01-11 2023-10-20 Incyte Corp Terapia combinada que comprende el inhibidor de la vía de proteínas tirosina cinasas de janus cinasas (jak) y el inhibidor de la proteína cinasa asociada a rho (rock).
WO2024241078A1 (en) * 2023-05-22 2024-11-28 Eli Lilly And Company Treatment or prevention of new-onset type 1 diabetes with baricitinib
WO2025226637A1 (en) 2024-04-22 2025-10-30 Incyte Corporation Combination therapy with an anti-colony stimulating factor 1 receptor antibody and a jak inhibitor

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
ES2293638T3 (es) 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
EP1104760B1 (en) 1999-12-03 2003-03-12 Pfizer Products Inc. Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents
BR0209325A (pt) 2001-05-03 2004-07-20 Hoffmann La Roche Forma de dosagem farmacêutica de mesilato de nelfinavir amorfo
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Pharmaceuticals, Inc. Delivery of drug esters through an inhalation route
DE60303009T2 (de) 2002-01-22 2006-07-13 Warner-Lambert Co. Llc 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-one
US20050107420A1 (en) * 2002-05-23 2005-05-19 Boehringe Ingelheim Pharma Gmbh & Co. Kg Combination of a PDE4 inhibitor and tiotropium or derivative thereof for treating obstructive airways and other inflammatory diseases
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
BRPI0516170A (pt) 2004-09-29 2008-08-26 Cordis Corp formas de dosagens farmacêuticas estáveis e amorfas de compostos de rapamicina
CA2624179A1 (en) 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
WO2008030382A1 (en) 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
US7718754B2 (en) 2007-07-30 2010-05-18 Kao Corporation Promoter for polycondensation reaction
PL2288610T3 (pl) 2008-03-11 2017-12-29 Incyte Holdings Corporation Azetydynowe i cyklobutanowe pochodne jako inhibitory jak
TWI665200B (zh) 2009-01-15 2019-07-11 英塞特公司 製造ｊａｋ抑制劑之方法及相關中間化合物
EP2565193B1 (en) 2009-01-23 2014-03-19 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
WO2012079075A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Deuterated phthalimide derivatives
BR112015003153A2 (pt) 2012-08-17 2017-07-04 Concert Pharmaceuticals Inc baricitinib deuterado

Also Published As

Publication number Publication date
EA201590321A1 (ru) 2015-06-30
EP2885303B1 (en) 2018-12-26
AU2013302519B2 (en) 2017-11-02
US9540367B2 (en) 2017-01-10
US20170189406A1 (en) 2017-07-06
WO2014028756A1 (en) 2014-02-20
US10842792B2 (en) 2020-11-24
US9931343B2 (en) 2018-04-03
AU2013302519A1 (en) 2015-02-12
EP3492472A1 (en) 2019-06-05
IN2015DN01102A (es) 2015-06-26
EP2885303A1 (en) 2015-06-24
MX2015002040A (es) 2015-06-05
ES2717279T3 (es) 2019-06-20
CA2880083A1 (en) 2014-02-20
US20150218158A1 (en) 2015-08-06
US20180221374A1 (en) 2018-08-09
EA031716B1 (ru) 2019-02-28
BR112015003153A2 (pt) 2017-07-04

Similar Documents

Publication Publication Date Title
MX361499B (es) Baricitinib deuterado.
MX2015001246A (es) Ibrutinib deuterado.
MY163187A (en) Novel imidazo-oxazine compound or salt thereof
MY171055A (en) 3,5-disubstituted alkynylbenzene compound and salt thereof
IN2015DN00960A (es)
PH12015502031B1 (en) Tetrahydropyrrolothiazine compounds
MX2015008829A (es) Momelotinib deuterado.
MY182082A (en) Biheteroaryl compounds and uses thereof
PH12015501993A1 (en) Pyrazole-amide compound and medicinal uses therefor
CR20140306A (es) Fluormetil -5,6-dihidro-4h-[1,3] oxazinas
IN2012DE00621A (es)
PH12015500900B1 (en) A stabilized pemetrexed formulation
EA201490761A1 (ru) R(+)-n-формилпропаргиламиноиндан
IN2012DE00620A (es)
IN2014DN07996A (es)
HK1222848A1 (zh) 用作alk抑制剂的吡咯并三嗪
PH12015501146A1 (en) Hydantoin derivative
IN2014DN10669A (es)
GB201020397D0 (en) Compounds
MX2015012610A (es) Pacritinib deuterizado.
MX2015001134A (es) Compuestos terapeuticos.
UA87694U (uk) Сполука 4,5,6,7-тетрагідро-3н-2-n-(пара-метоксифенациламіно)-азепіну гідрохлорид з потенційними фізіологічними властивостями
UA87695U (uk) Сполука 4,5,6,7-тетрагідро-3н-2-n-(пара-метоксифенациламіно)-азепіну гідрохлорид, що має інотропну активність
UA87254U (ru) Соединение 1,1-диэтилкарбокси-2-метокси-2-трифторметилэтилен с потенциальными физиологическими свойствами
UA89447U (ru) Соединение 1,1-диэтилкарбокси-2-хлор-2-трифторметилэтилен с потенциальными физиологическими свойствами

Legal Events

Date Code Title Description
FG Grant or registration